We systematically searched three electronic databases (up to 31 October 2020) for identifying placebo-controlled or head-to-head RCTs that used SGLT-2 inhibitors for treatment of NAFLD. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.